# Semaglutide

## Ozempic inj 4mg/3mL

| TAH Drug Code      | [IOZE4](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IOZE4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Type 2 diabetes mellitus. Prophylaxis of disorder of cardiovascular system with type 2 diabetes mellitus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | SC， 0.25 mg once weekly for 4 weeks， then increase to 0.5 mg once weekly; may increase to maximum 1 mg once weekly if additional glycemic control is needed after at least 4 weeks of the 0.5 mg weekly dosage.                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2. Known hypersensitivity to semaglutide or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Adverse Effects    | Common: Hypoglycemia (Monotherapy， 1.6-3.8%; combination therapy， 6-30%)， Abdominal pain (Diabetes， 5.7-11%; weight management， 15-20%)， Constipation (Diabetes， 3.1-6%; weight management， 6-24%)， Diarrhea (Diabetes， 8.5-10%; weight management， 22-30%)， Nausea (Diabetes， 11-20.3%; weight management， 42-44%)， Vomiting (Diabetes， 5-9.2% ; weight management， 24-36%)， Headache (14-17%) Serious: Increased heart rate， Medullary thyroid carcinoma， Cholecystitis (0.6-0.8%)， Cholelithiasis (0.4-3.8%)， Pancreatitis， Anaphylaxis， Hypersensitivity reaction， Retinopathy due to diabetes mellitus， Anxiety， Depression， Suicidal thoughts， Angioedema |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/semaglutide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

## Rybelsus 7mg

| TAH Drug Code      | [ORYB](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ORYB)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; can be used as monotherapy if patient is intolerant or contraindicated to metformin or be used in combination with other diabetes medications.                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | 3 mg orally QD for 30 days， then increase dose to 7 mg QD. Dose may be increased to 14 mg QD if additional glycemic control is needed after at least 30 days receiving 7-mg dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | [Common] Hypoglycemia (Monotherapy， 1.6-3.8%; combination therapy， 6-30% )， Abdominal pain (Diabetes， 5.7-11% ; weight management， 15-20% )， Constipation (Diabetes， 3.1-6% ; weight management， 6-24% )， Diarrhea (Diabetes， 8.5-10% ; weight management， 22-30% )， Nausea (Diabetes， 11-20.3% ; weight management， 42-44% )， Vomiting (Diabetes， 5-9.2% ; weight management， 24-36% )， Headache (14-17% ) [Serious] Increased heart rate， Medullary thyroid carcinoma， Cholecystitis (0.6-0.8% )， Cholelithiasis (0.4-3.8% )， Pancreatitis， Anaphylaxis， Hypersensitivity reaction， Retinopathy due to diabetes mellitus， Angioedema |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| More Info          | [UpToDate](https://www.uptodate.com/contents/semaglutide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

## RYBELSUS 14mg

| TAH Drug Code      | [ORYB14](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ORYB14)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; can be used as monotherapy if patient is intolerant or contraindicated to metformin or be used in combination with other diabetes medications.                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | 3 mg orally QD for 30 days， then increase dose to 7 mg QD. Dose may be increased to 14 mg QD if additional glycemic control is needed after at least 30 days receiving 7-mg dose.                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Known hypersensitivity to semaglutide or any component of the product.                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | [Common] Hypoglycemia (Monotherapy， 1.6-3.8%; combination therapy， 6-30% )， Abdominal pain (Diabetes， 5.7-11% ; weight management， 15-20% )， Constipation (Diabetes， 3.1-6% ; weight management， 6-24% )， Diarrhea (Diabetes， 8.5-10% ; weight management， 22-30% )， Nausea (Diabetes， 11-20.3% ; weight management， 42-44% )， Vomiting (Diabetes， 5-9.2% ; weight management， 24-36% )， Headache (14-17% ) [Serious] Increased heart rate， Medullary thyroid carcinoma， Cholecystitis (0.6-0.8% )， Cholelithiasis (0.4-3.8% )， Pancreatitis， Anaphylaxis， Hypersensitivity reaction， Retinopathy due to diabetes mellitus， Angioedema |
| Pregnancy          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | Unknown                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| More Info          | [UpToDate](https://www.uptodate.com/contents/semaglutide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

